Fierce Biotech reports that Novartis CEO, Joe Jimenez, says that the company will switch away from expecting single indication drugs to result in blockbuster status (i.e. > $1 B in annual sales). Instead, Novartis will introduce drugs, gain approval as quickly as possible, and then extend the drug's indications -- perhaps in niche markets -- to cobble together its $1 B in annaul sales across all the indications.
In other words, they will continue to do what they have been doing in cancer fields for a long time. Just build em one block at a time.
Posted by Bruce Lehr Mar 4th 2013.